Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq
Other stock markets
 21:00:00 13/05/2024 BST 		5-day change 1st Jan Change
2.23 USD +1.83% Intraday chart for Esperion Therapeutics, Inc. +5.19% -25.42%
05-07 Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell MT
05-07 Top Premarket Gainers MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Gainers
MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $137.7M, vs. Street Est of $83.9M
MT
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01
MT
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Steady Premarket Monday
MT
Top Premarket Gainers
MT
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
CI
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet
MT
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update
MT
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination
CI
North American Morning Briefing : Stock Futures -2-
DJ
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q4 Revenue $32.3M, vs. Street Est of $28.7M
MT
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Tech Stocks Gains
MT
Esperion Therapeutics, Daiichi Sankyo Europe Settle Commercial Dispute With $125 Million Amendment in Collaboration
MT
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
CI
U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet
CI
Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023
CI
Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. News Esperion Therapeutics, Inc.
  5. Highlights